Purpose: There is substantial germline genetic variability within angiogenesis pathway genes, thereby causing interindividual differences in angiogenic capacity and resistance to antiangiogenesis therapy. We investigated germline polymorphisms in genes involved in VEGF-dependent and -independent angiogenesis pathways to predict clinical outcome and tumor response in metastatic colorectal cancer (mCRC) patients treated with bevacizumab and oxaliplatin-based chemotherapy.
Introduction
Angiogenesis is a universal requirement for the growth of solid tumors beyond the limits of oxygen diffusion from the existing vasculature (1, 2) . Inhibition of angiogenesis has proven to be beneficial in multiple types of malignancies, including colon cancer (3) . VEGF-A is one of the major regulators of both physiologic and pathologic angiogenesis. Rapid proliferation of tumor cells and poor blood flow suggest a hypoxia-conducive environment in different areas of tumors. Under hypoxic conditions, hypoxia-inducible factor (HIF) binds to the hypoxia response element present in the VEGF-A gene, thus inducing the transcription of VEGF-A protein. Circulating VEGF-A binds to VEGF receptor (VEGFR)-1 and VEGFR-2 stimulating the recruitment and proliferation of endothelial cells (4) (5) (6) . Bevacizumab is a humanized monoclonal antibody (mAB) directed against VEGF-A (7).
Treatment strategies incorporating bevacizumab have shown efficacy in metastatic colorectal cancer (mCRC; refs. 8, 9) . The majority of previously untreated mCRC patients are treated with bevacizumab in combination with oxaliplatin and infusional 5-fluorouracil/leucovorin or capecitabine (FOLFOX or XELOX; ref. 9 ). The addition of bevacizumab to first-line oxaliplatin-based chemotherapy in mCRC was shown to significantly prolong the median progression-free survival (PFS; from 8.0 to 9.4 months, corresponding to an HR of 0.83; P ¼ 0.0023). Median overall survival (OS) was 21.3 months in the bevacizumab group and 19.9 months in the placebo group (HR: 0.89; P ¼ 0.077). The response rate (RR) was similar in both arms (38% vs. 38%; OR: 1.00; P ¼ 0.99; ref. 10) .
The identification of biomarkers that may influence the efficacy of bevacizumab in combination with oxaliplatinbased chemotherapy is of considerable interest (3, 7) . Despite the effects of bevacizumab in unselected mCRC patients, the ability to target therapy toward well-selected subgroups of patients would increase the likelihood of benefit and would improve cost-effectiveness and therapeutic outcomes. Current evidence indicates potential predictive value for germline polymorphisms affecting genes of the VEGF pathway in patients receiving bevacizumab (11) (12) (13) (14) . This is not surprising because angiogenesis depends largely on the response of the host. There is substantial inherited genetic variability within angiogenesis pathway genes, thereby causing interindividual differences in angiogenic capacity and resistance to bevacizumab. In a pioneering study, Schneider and colleagues investigated 5 VEGF and 2 VEGFR-2 polymorphisms in a retrospective subset analyses of the E2100 trial cohort (paclitaxel AE bevacizumab in metastatic breast cancer) and found 2 VEGF genotypes (VEGF 2578 A/A and VEGF 1154 A/A) predicting a superior OS for patients in the combination, but not in the control arm, thus indicating a predictive marker (14) .
Recent studies in several experimental models suggest that alternative angiogenic factors are potentially involved in resistance to anti-VEGF treatment (15) (16) (17) . Sustained tumor angiogenesis could occur through VEGF-independent mechanisms, thus indicating that these angiogenic factors may serve as predictors of bevacizumab efficacy. We recently reported a functional germline polymorphism in interleukin (IL)-8 (251 T/A, A-allele associated with increased IL-8 protein levels), a potent VEGF-independent proangiogenic factor, significantly associated with lower RR in a phase II trial in patients with ovarian cancer treated with bevacizumab and cyclophosphamide (12) .
In the present study, we investigated germline polymorphisms in a comprehensive panel of angiogenesis genes to predict clinical outcome and tumor response in mCRC patients treated with first-line bevacizumab and oxaliplatin-based chemotherapy. We analyzed VEGFdependent genes, such as VEGF-A, VEGFR-2, HIF1a, aryl hydrocarbon receptor nuclear translocator (ARNT), and neuropilin-1 (NRP1), and VEGF-independent angiogenesis genes, such as IL-1b, IL-6, IL-8, IL receptor-1/2 (CXCR1 and CXCR2), leptin, tissue factor (TF), endostatin (ES), fibroblast growth factor receptor (FGFR)-4, insulin-like growth factor (IGF)-1/2, IGF receptor (IGFR1), nuclear factor kappaB (NF-kB), epidermal growth factor (EGF), EGF receptor (EGFR), COX-2, TNF-a and -b, intercellular adhesion molecule (ICAM)-1, and matrix metalloproteinases (MMP)-2 and -7.
Patients and Methods

Eligible patients
A total of 132 patients with histopathologically confirmed mCRC and first-line treatment with FOLFOX or XELOX and bevacizumab were included in this retrospective study. These patients received first-line treatment with FOLFOX or XELOX and bevacizumab (5 mg/kg on day 1 of a 2-week cycle when given with FOLFOX, 7.5 mg/kg on day 1 of a 3-week cycle for XELOX) between April 2004 and October 2009 at the Norris Comprehensive Cancer Center/ University of Southern California (NCCC/USC) or the Los Angeles County/USC Medical Center (LAC/USCMC) and the Division of Clinical Oncology, Medical University of Graz (MUG), Austria. Patients included in the study were required to be 18 years or older, have present 1 or more unidimensionally measurable lesion, response data available during at least 2 cycles of bevacizumab plus FOLFOX or XELOX, and have not received prior systemic therapy for mCRC or previous treatment with mABs. At the time of treatment initiation, the following criteria were used as contraindication for bevacizumab: brain metastases, highdose nonsteroidal anti-inflammatory drugs, serious nonhealing wound, prior pulmonary embolism or recent venous thromboembolic event, any arterial thromboembolic event, and/or baseline grade 2 or more proteinuria. Patient data were collected retrospectively through medical chart review by a medical oncologist (H. Singh). For quality control purposes, all clinical data were independently reviewed by a second medical oncologist (A. El-Khoueiry). Whole-blood samples were collected at the time of diagnosis and stored at À80
C. Blood samples from 119 patients were available for the current genetic analyses. This retrospective study was approved by the Institutional Review Boards of USC and MUG. All patients signed an informed consent for the analysis of molecular correlates. Baseline clinical examinations and staging CT scans were carried out within 4 weeks of starting treatment and
Translational Relevance
Germline variants in VEGF-dependent angiogenesis genes have been linked to bevacizumab resistance in recent studies. Here, we investigated germline polymorphisms in genes involved in VEGF-dependent and -independent angiogenesis pathways to predict clinical outcome and tumor response in metastatic colorectal cancer patients treated with bevacizumab and oxaliplatin-based chemotherapy. We hypothesized that these functional gene variants cause interindividual differences in angiogenic capacity and bevacizumab resistance. Our findings suggest that overall survival and tumor response vary according to epidermal growth factor, insulin-like growth factor-1, and CXCR1 genotypes, thus representing valuable biomarkers validation in larger prospective cohorts. repeated every 8 weeks until progression. The Response Evaluation Criteria in Solid Tumors (RECIST) were used to assess response.
Candidate polymorphisms
Genes and polymorphisms known to modulate VEGFdependent and -independent angiogenesis have been selected on the basis of public literature resources and databases. Stringent and predefined criteria were used and included (i) credible scientific basis to support a gene's involvement in angiogenesis signaling pathways; (ii) polymorphism that could alter the function of the gene in a biologically relevant manner (either published data or predicted function using functional single-nucleotide polymorphism (F-SNP) database; refs. 18, 19) ; and (iii) minor allele frequency of 10% or more in Caucasians (for relative allelic frequencies of the polymorphisms in different ethnicities, we refer to the population genetics section in the Ensembl Genome Browser: http://uswest.ensembl.org/ index.html). As it was not possible to select all angiogenesis signaling-related genes and polymorphisms matching these criteria, this study focused on the most promising (Tables 1 and 2 ).
Genotyping
Genomic DNA was extracted from peripheral blood using the QIAamp Kit (Qiagen). The majority of the samples were tested using PCR-RFLP analysis. Briefly, forward and reverse primers were used for PCR amplification, PCR products were digested by restriction enzymes (New England Biolabs), and alleles were separated on 4% NuSieve ethidium bromide-stained agarose gel. If no matching restriction enzyme could be found, samples were analyzed by direct DNA sequencing. The dinucleotide polymorphisms were determined by a 5 0 -end [g-33 P]ATP-labeled PCR protocol with a few modifications. In brief, DNA template, deoxynucleotide triphosphates (dNTP), 5 0 -end [g- 33 P]ATP-labeled primer, unlabeled complementary primer, Taq Polymerase (PerkinElmer), and PCR buffer were used in PCR. The reaction products were separated on a 6% denaturing PAGE DNA-sequencing gel, which was vacuum blotted for 1 hour at 80 C and exposed to XAR Film (Eastman Kodak) overnight. For quality control purposes, a total of 5% PCR-RFLP analyzed samples were reanalyzed by direct DNA sequencing. Patients' characteristics and clinical outcome were unknown to the investigator conducting the genetic analyses (A. Gerger).
Statistical analysis
The endpoints of the study were PFS, OS, and RR. The PFS was calculated from the time of the first day of treatment until the first observation of disease progression or death from any cause. OS was defined as the time from the first day of treatment to death from any cause. If a patient was alive with disease progression, PFS and OS were censored at the time of last follow-up. RR was categorized into 2 groups as follows: complete or partial response and stable or progressive disease. With 119 patients, there was an 80% power to detect a minimum HR of 1.7 and 1.8, and 34% tumor response differences across the range of minor allele frequencies (0.1-0.5), using a dominant model for PFS, OS, and RR, respectively. The NF-kB repeat polymorphism was analyzed by categorizing 3 groups as follows: (i) carrying both alleles with less than 24 repeats; (ii) carrying 1 allele with less than 24 repeats; and (iii) carrying both alleles with 24 repeats or more. For the VEGFR-2 repeat polymorphisms, we combined the 14 with the 13 CA repeats and categorized in 11 of 11, 11 of 13, and 13 of 13 CA repeats. Allelic distribution of the polymorphisms by ethnicity for deviation from Hardy-Weinberg equilibrium and the allelic frequencies of each polymorphism between different ethnic groups were tested using the c 2 test. The associations between polymorphisms and baseline demographic and clinical characteristics and RR were examined using contingency tables and the Fisher exact test. The associations of polymorphisms with PFS and OS were analyzed using Kaplan-Meier curves and the log-rank test. The true mode of inheritance of all polymorphisms tested is not established yet, and we assumed a codominant, additive, dominant, or recessive genetic model where appropriate. In the multivariate Cox regression analysis for PFS and OS and the logistic regression analysis for RR, the models were adjusted for sex, age, primary tumor site, histologic differentiation, metastatic site, number of metastatic sites, chemotherapy backbone (FOLFOX or XELOX), and study site (hospital) stratified by ethnicity. P values for all polymorphisms were adjusted for multiple testing by using a modified test of Conneely and Boehnke (P act ) that was applied for the correlated tests due to linkage disequilibrium and different modes of inheritance considered (20) . Recursive partitioning (RP), including crossvalidation, was used to explore and identify polymorphism interactions associated with RR, PFS, and OS using the rPart function in S-plus. Case-wise deletion for missing polymorphisms was used in univariate and multivariate analyses. In the RP analysis, all patients with at least 1 polymorphism result available were included. All analyses were carried out using the SAS statistical package version 9.2 (SAS Institute Inc.).
Results
Baseline patient characteristics and the association with clinical outcome and RR are summarized in Table 3 .
There were no statistically significant differences in age and sex between the patients from USC and MUG; however, more MUG patients had rectosigmoid tumors (28% vs. 6%) and received FOLFOX (80% vs. 43%), compared with USC patients. The median age at time of diagnosis was 56 years (range: 28-81). The median follow-up time was 3.5 years (range: 0.3-6.5) and the median PFS and OS were 11.2 months (95% CI: 8.4-13.7) and 27.9 months (95% CI: 22.4-32.4), respectively. Sixty-four patients (48.5%) showed complete or partial tumor response, 63 patients (47.7%) had stable or progressive disease; for 5 patients (3.8%), response data were not available. The genotyping quality control by direct DNA sequencing provided a genotype concordance of 99% or more. Genotyping was successful in at least 90% of cases in each polymorphism analyzed, except the NF-kB repeat polymorphism with 84%. The allelic frequencies for all polymorphisms were within the probability limits of Hardy-Weinberg equilibrium. VEGF-A rs2010963, rs699947, rs1570360, and rs833061 were in linkage disequilibrium (D 0 ranged from 0.79 to 1.0 and r 2 ranged from 0.13 to 0.81). VEGF-A rs3025039 was not in linkage disequilibrium with the other 4 VEGF-A gene variants (D 0 < 0.16 and r 2 < 0.01). The VEGFR-2 polymorphisms were not in strong linkage disequilibrium (D 0 ¼ 0.47 and r 2 ¼ 0.04). Genotype frequencies for all polymorphisms in each ethnicity are summarized in Supplementary  Table S1 . 
Gene variants and PFS
In the univariate analysis, the minor allele of HIF1a rs11549465 C>T was significantly associated with increased PFS. Patients carrying at least one T allele showed a median PFS of 11.7 months. In contrast, patients homozygous C/C had a median PFS of 10.2 months (HR: 0.55; 95% CI: 0.31-0.99; P ¼ 0.038). None of the other tested polymorphisms were associated with PFS. In multivariate analysis stratified by ethnicity and multiple testing including all polymorphisms, HIF1a rs11549465 C>T did not remain significantly associated with PFS (HR: 0.65; 95% CI: 0.34-1.22; adjusted P ¼ 0.18; P act ¼ 0.362; Table 4 ).
Gene variants and OS
In the univariate analysis, the minor alleles of EGF rs444903 A>G and IGF-1 rs6220 A>G were significantly associated with increased OS. Patients carrying at least one G allele in EGF rs444903 A>G showed a median OS of 32.4 months. In contrast, patients homozygous A/A had a median OS of 21.9 months (HR: 0.54; 95% CI: 0.33-0.88; P ¼ 0.011). Patients harboring the minor allele of IGF-1 rs6220 A>G showed a median OS of 32.4 months compared with 22.1 months for those harboring homozygous A/A (HR: 0.51; 95% CI: 0.32-0.83; P ¼ 0.005; Table 4 ; Fig. 1) . None of the other tested polymorphisms showed a statistically significant association with OS. In the multivariate analysis stratified by ethnicity, the minor alleles of EGF rs444903 A>G and IGF-1 rs6220 A>G remained significantly associated with increased OS (HR: 0.52; 95% CI: 0.31-0.87; adjusted P ¼ 0.012 and HR: 0.60; 95% CI: 0.36-0.99; adjusted P ¼ 0.046, respectively). In multiple testing, EGF rs444903 A>G and IGF-1 rs6220 A>G did not remain significantly associated with OS (P act ¼ 0.664 and 0.780, respectively).
Gene variants and tumor response
CXCR1 rs2234671 G>C, CXCR2 rs2230054 T>C, EGFR rs2227983 G>A, and VEGFR-2 rs2305948 C>T were significantly associated with RR. Patients homozygous for the wild-type allele of CXCR1 rs2234671 G>C and VEGFR-2 rs2305948 C>T were more likely to show higher tumor response (71% and 57%, respectively) than patients carrying 1 (37% and 29%, respectively) or 2 minor alleles (17% and 33%; P < 0.001 and P ¼ 0.024, respectively). In CXCR2 rs2230054 T>C and EGFR rs2227983 G>A, patients harboring the wild-type genotype had a significantly lower RR (38% and 43%, respectively) than patients heterozygous (56% and 55%, respectively) or homozygous for the minor allele (79% and 82%; P ¼ 0.008 and P ¼ 0.024, respectively; Table 4 ). None of the other analyzed polymorphisms predicted RR. In logistic regression analysis, CXCR1 rs2234671 G>C remained significantly associated with RR (P < 0.001). In multiple testing including all polymorphisms, CXCR1 rs2234671 G>C remained statistically significant for RR (P act ¼ 0.003).
Gene variant interactions by RP
When RP was utilized to construct decision trees as predictive models for PFS, OS, and RR to classify patients based on the gene variants, high-and low-risk patient subgroups were identified. In the resultant tree for PFS, the most important factor that determined PFS in our study cohort was HIF1a rs11549465 C>T. Patients carrying the combination of HIF1a rs11549465 C>T wild-type and the minor allele of VEGF rs699947 C>A and EGFR rs2227983 G>A wild-type showed a PFS of 7.8 months compared with 11.7 months in patients harboring at least 1 minor allele of HIF1a rs11549465 C>T (HR: 2.66; 95% CI: 1.30-5.42; P < 0.001). The resultant tree for OS showed that patients heterozygous or homozygous for the minor alleles of IGF-1 rs6220 A>G and IL-6 rs1800795 G>C showed an OS of 60 months compared with 21.7 months in patients harboring the IGF-1 rs6220 A>G wild-type (HR: 2.67; 95% CI: 1.25-5.66; P < 0.001). For RR, CXCR1 rs2234671 G>C was the main split criteria in the decision tree, but no other gene variants were shown to improve the prediction success.
Clinical outcome and tumor response by ethnicity
When the allelic frequencies of each polymorphism, which was significantly associated with clinical outcome or tumor response, were tested between ethnic groups, we found a significant difference for CXCR2 rs2230054 T>C, VEGFR-2 rs2305948, and EGF rs444903 A>G (P ¼ 0.017, P ¼ 0.018, and P ¼ 0.005, respectively). The minor allele of EGF rs444903 A>G remained significantly associated with increased OS (HR: 0.47; 95% CI: 0.24-0.93; P ¼ 0.021) in Caucasians but not in Asians and Hispanics (HR: 0.65; 95% CI: 0.21-1.98; P ¼ 0.42 and HR: 0.50; 95% CI: 0.17-1.50; P ¼ 0.21, respectively). African Americans were excluded from subanalyses because of the small number in our study cohort (n ¼ 5). CXCR2 rs2230054 T>C remained significantly associated with RR in Caucasians (wild-type 35%, heterozygous for the minor allele 60%, and homozygous for the minor allele 100%; P ¼ 0.035) but not in Asians and Hispanics (P ¼ 0.351 and P ¼ 0.191, respectively). Patients homozygous for the wild-type allele of VEGFR-2 rs2305948 C>T were more likely to show higher tumor response than patients carrying 1 or 2 minor alleles, but this effect did not remain significant in subanalyses for ethnicity (Caucasian: P ¼ 0.17; Asian: P ¼ 0.055; and Hispanic: P ¼ 0.86).
Discussion
Even though thousands of patients have been enrolled in randomized clinical trials of bevacizumab, only few insights are available about specific subgroups of patients who may actually benefit (21) . At the same time, no biomarkers are currently available to quantify the contribution of bevacizumab to the activity of cytotoxic drugs. Because the efficacy of bevacizumab may vary between different chemotherapy backbones, the current priority in translational research is focused on biomarker response or resistance to combined therapies. In this investigation, we focused on host-related VEGF-dependent and -independent angiogenic biomarkers to predict survival and tumor response of mCRC patients treated with bevacizumab and oxaliplatin-based chemotherapy. This study has been conducted to draw biological observations to be validated in biomarker-embedded trials.
In mCRC, Loupakis and colleagues found no association between VEGF and VEGFR-2 polymorphisms and clinical outcome in 57 patients enrolled in a phase II trial of FOLFOXIRI plus bevacizumab as first-line treatment (22) . One report by Formica and colleagues suggested that VEGF rs1570360 and VEGF rs2010963 genotypes predict PFS and RR in patients receiving bevacizumab and FOLFIRI (13) . A genetic interaction profile, including VEGF rs2010963, by Pander and colleagues was associated with PFS in mCRC patients treated with XELOX plus bevacizumab (23) . Although this study did not confirm these findings, we identified 2 other VEGF-dependent gene polymorphisms associated with PFS and RR in mCRC patients treated with bevacizumab and oxaliplatin-based chemotherapy. The minor allele of HIF1a rs11549465 C>T, which has been recently associated with higher HIF1a protein expression, predicted an increased PFS in the univariate analysis (24) . The VEGF-A promoter contains a hypoxic response element that can bind HIF1a and initiate transcriptional activation of the VEGF-A gene (25) . Although the association found in our study is biologically plausible and in concordance with several studies showing that patients with VEGF-A activation more likely benefit from bevacizumab treatment, HIF1a rs11549465 C>T did not remain significant in the multivariate analysis (26, 27) . In VEGFR-2 rs2305948 C>T, the minor allele predicted a lower RR in the univariate analysis when analyzed in all study patients. However, this effect did not remain significant in subanalyses for ethnicity. VEGFR-2 rs2305948 C>T is associated with microvessel density (MVD) in CRC, with the C/T and T/T genotypes showing a significantly higher MVD than the wild-type allele (28) . Taking into account the functional effect of this polymorphism and the association found in our study, we suggest that the variant allele in the VEGFR-2 gene may drive angiogenesis independent of VEGF-A ligand binding.
Because alternative angiogenic mechanisms are potentially involved in resistance to bevacizumab, we investigated a comprehensive panel of VEGF-independent gene polymorphisms. CXCR1 rs2234671 G>C represented the most promising polymorphism in our study, predicting RR in multivariate analysis and multiple testing, whereas CXCR2 rs2230054 C>T lost its significance in multivariate analysis and multiple testing. IL-8 exerts its angiogenic properties on endothelial cells through interaction with its cognate receptors CXCR1 and CXCR2 (29) . Induction of IL-8 preserved the angiogenic response in HIF1a-deficient colon cancer cells, suggesting that IL-8-dependent angiogenesis is independent of VEGF (30) . The detailed molecular mechanisms involved in how the CXCR1 rs2234671 G>C and CXCR2 rs2230054 C>T polymorphisms exert effects on mCRC and predict RR in bevacizumab-and FOLFOX-or XELOX-treated patients are unclear. We used the F-SNP database to predict the functional effects of these gene variants. F-SNP gathers computationally predicted functional information about polymorphisms, particularly aiming to facilitate identification of disease-related polymorphisms in association studies. Specifically, it provides information about potential deleterious effects of polymorphisms with respect to major molecular functions (18, 19) . When used for the CXCR gene variants, F-SNP predicted changes both in splicing regulation and posttranslation for CXCR1 rs2234671 G>C and in splicing regulation and transcriptional regulation for CXCR2 rs2230054 C>T, thus supporting a biological function and the effects seen in our study.
In a recent study by Cascone and colleagues using mouse xenograft models of human lung adenocarcinomas, EGFR activation in stromal cells but not in tumor cells has been shown to be involved in bevacizumab resistance, indicating a host-regulated process of VEGFindependent angiogenesis (31). We found a functional germline polymorphism in EGFR associated with RR in univariate analysis in our study cohort. Patients harboring at least 1 minor allele of EGFR rs2227983 G>A were more likely to show a higher tumor response than patients homozygous for the wild-type allele. The minor allele was previously found to be associated with attenuated EGFR ligand binding (32) . Our finding is therefore consistent with the functional effect of this polymorphism, as decreased EGFR signaling may attenuate the VEGF-independent angiogenic capacity.
Another finding of our study was that EGF rs4444903 A>G and IGF-1 rs6220 A>G predict OS in the univariate and multivariate analyses. The minor allele of EGF rs4444903 A>G is transcriptionally more active than the wild-type allele and has been associated with higher EGF serum levels (33) . In a recent study by Pander and colleagues, EGF rs4444903 A>G was not associated with PFS in mCRC patients treated with XELOX plus bevacizumab (34) . EGF signaling contributes to cell proliferation and angiogenesis; therefore, the favorable effect of the EGF rs4444903 minor allele seen in our study may be counterintuitive. EGF signaling promotes angiogenesis not only by exerting direct effects on endothelial cells but also by upregulating VEGF mRNA expression (35) . This partly VEGF-dependent mechanism may be responsible for the increased OS survival in bevacizumab-treated patients harboring the minor allele. Similar potential mechanisms may also apply for IGF-1 rs6220 A>G, as the minor allele shows higher IGF-1 plasma levels, which is associated with increased VEGF mRNA expression (36, 37) . On the other hand, it has been shown that at specific concentrations that vary between experimental model, EGF induces apoptosis and growth inhibition rather than cell proliferation (38) (39) (40) . According to such findings and the fact that EGF rs4444903 A>G predicts OS but not PFS or RR, this polymorphism could represent a prognostic rather than a predictive biomarker, which is in concordance with several studies showing that the EGF-upregulating genotype predicts significantly better survival rates (41) .
We conducted multiple testing because of the large number of independent genetic variants evaluated. Application of a modified test of Conneely and Boehnke for correlated tests resulted in a significant P act value only for CXCR1 rs2234671 G>C in predicting RR. Nevertheless, the biological plausibility and our translational findings hold promise for future investigations and warrant validation in a larger cohort. Investigating gene variant interactions using RP, we found that combinations of gene variants may improve the prediction success for PFS and OS, but not for RR, in our study cohort. Interestingly, VEGF rs699947 C>A and IL-6 rs1800795 G>C were included in the decision tree by RP for PFS and OS, respectively. The minor allele of VEGF rs699947 C>A is associated with lower VEGF serum levels and predicted the low PFS subgroup in RP analysis. This association is in concordance with several studies showing that patients with VEGF-A activation more likely benefit from bevacizumab treatment (26, 27) . The minor allele of IL-6 rs1800795 G>C is associated with lower IL-6 plasma levels and may therefore contribute to the high OS subgroup predicted in RP analysis. The fact that allelic frequencies of polymorphisms can differ between ethnic groups and influence the clinical effect, as seen in our study, points out the importance of ethnicity-specific analyses in future studies. Because of the combined treatment in our study and the lack of an appropriate control group, the results are not directly attributable to single-agent administration of bevacizumab but should be referred to the combined treatment of bevacizumab with FOLFOX or XELOX.
This study provides evidence that functional germline polymorphisms in VEGF-dependent and -independent angiogenesis genes predict tumor response and survival in mCRC patients treated with bevacizumab and FOLFOX or XELOX. Biomarker-embedded translational trials are warranted to validate these findings.
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